This 2018 systematic review and network meta-analysis evaluated the impact of FDA-approved weight-loss medications—phentermine-topiramate, liraglutide, naltrexone-bupropion, lorcaserin, and orlistat—on cardiometabolic risk factors in obese adults. Analyzing 28 randomized controlled trials encompassing 29,018 participants, the study found that these medications led to modest reductions in fasting blood glucose (mean decrease of
